FDA Press Office Shakeup Generates Bad Headlines For Agency With Charges Of Ageism
Executive Summary
A young FDA official’s decision to boot three seasoned press specialists from the Public Affairs Office may be an embarrassment for an agency seeking to burnish its image.
You may also be interested in...
FDA PR About-Face
A recent effort to build a new type of public affairs staff for the Food & Drug Administration may be backfiring.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.